Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Auxilium amends agreement with UK biopharmaceutical
Under the amended agreement, Cobra will complete only one biologics license application batch of the active ingredient for AA4500, the company's injectable enzyme for the treatment of Dupuytren's
Under the amended agreement, Cobra will complete only one biologics license application batch of the active ingredient for AA4500, the company's injectable enzyme for the treatment of Dupuytren's
This trial is the first follow-on study to Genta's phase III trial of Genasense plus dacarbazine that showed benefit across multiple clinical endpoints in patients with advanced melanoma
The company plans to initiate its phase III program before year-end with the luteinizing hormone-releasing hormone antagonist compound, cetrorelix. The first study of this phase III program will
MLN3897 is one of several small molecules included in the company's small molecule inflammation collaboration with sanofi-aventis. MLN3897 is a small molecule antagonist of CCR1, a chemokine receptor
As part of the scheme, a free vaccine program for women aged 19-26 will also be delivered by doctors. CSL said that the immunization program will commence in
Upon final approval, Teva's sumatriptan succinate tablets will be the AB-rated generic equivalent of GlaxoSmithKline's Imitrex tablets. Final approval is expected upon expiry of patent protection for the
The planned cut-back will see 2,200 employees in Pfizer’s sales organization lose their jobs in an effort to compensate for market changes and sales losses due to expiration
The company’s hospital-based products division, Abraxis Pharmaceutical Products, expects to commence marketing ampicillin and sulbactam immediately. The approval is the tenth product approval the company has received this
The primary endpoint is seroprotection four weeks after the third immunization. Data for the entire study population show that after two doses, Heplisav provided 98.5% seroprotection versus Engerix-B’s
Pfizer said the decision to discontinue its participation in the asenapine development program is an outcome of a commercial analysis of the compound as a part of its